Delhi — Delhi-based gut-health startup Guttify is planning to raise approximately ₹20 crore in its next funding round to accelerate product development, strengthen diagnostics and expand distribution across Tier-1 and Tier-2 cities, the company said.
Growth metrics underpin fundraising
The proposed fundraise follows what Guttify described as a period of rapid momentum for its consumer platform. The company reported a 67 per cent quarter-on-quarter growth, around 20 per cent monthly growth in its user base and a 40 per cent repeat-user rate, according to the company’s public statements.
Guttify’s most recent valuation was cited at approximately ₹54 crore. Earlier fundraising includes an approximately ₹4 crore follow-on round in February 2026 and an extended seed round worth roughly USD 360,000 in May 2025. The startup has raised more than ₹10 crore cumulatively to date, with participation from a family office associated with Unichem Laboratories, existing investors and several high-net-worth individuals, the company said.
Planned use of funds and market positioning
Guttify said the upcoming funds will be directed towards:
- Product innovation across digestive and metabolic wellness categories such as constipation, bloating, digestion and liver health;
- Enhancing technology and diagnostic capabilities, including lab and digital tools;
- Consumer education to broaden awareness of gut health and preventive wellness; and
- Expanding distribution in both Tier-1 and Tier-2 Indian markets.
The company positions itself as a consumer-facing platform focused on everyday gut wellness and high-frequency digestive health needs. The move comes amid a broader shift in India where gut health conversations are moving from niche wellness forums into mainstream consumer health, driven by increased awareness of digestion, metabolic health and the microbiome.
Funding history and investors
Guttify’s funding trajectory includes the recent follow-on of about ₹4 crore and the earlier extended seed round of approximately USD 360,000. The startup said the cumulative funds raised exceed ₹10 crore, with participation from the family office linked to Unichem Laboratories and various domestic and international high-net-worth individuals, including named investors in its disclosures.
| Metric | Figure |
|---|---|
| Planned raise | ₹20 crore |
| Latest valuation | ₹54 crore |
| Quarter-on-quarter growth | 67% |
| Monthly user growth | ~20% |
| Repeat-user rate | 40% |
Industry observers say consumer interest in digestive and metabolic wellness has increased in recent years, helped by greater health awareness, increased access to health information online and expanding direct-to-consumer health services. Startups in the space are focusing on combining diagnostics, personalised guidance and over-the-counter products to capture high-frequency needs.
Regulators and established healthcare institutions continue to emphasise evidence-based claims. Public health agencies such as the Indian Council of Medical Research (ICMR) and international bodies like the World Health Organization (WHO) recommend that consumers consult qualified medical practitioners before starting any treatment or supplement regimen. Consumers should be cautious of unverified claims and seek professional advice for persistent gastrointestinal symptoms.
"The proposed fundraise will help the company scale diagnostics and consumer education while broadening its product portfolio," the company said in its statement.
Guttify’s stated strategy to expand into Tier-2 markets reflects a wider trend among health startups seeking deeper penetration beyond metropolitan centres. How effectively the company translates user growth into sustainable clinical outcomes and regulatory-compliant products will determine its longer-term position in the competitive gut-health market.
Readers are advised that WE NEWS content is not a substitute for professional medical advice. Individuals with health concerns should consult a qualified doctor or appropriate public health authority.
